newsfilter
← Latest News
GlobeNewswire·

Aura Biosciences Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Phase 3 CoMpass trial fully enrolled with 108 patients, exceeding enrollment target; on track for topline data in 2H 2027 Strategic operating plan refined to focus on development of bel-sar in ocular oncology Interim